Gilead Sciences (GILD) News Today $92.57 +1.48 (+1.62%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Gilead Sciences to Present at Upcoming Investor ConferenceDecember 21 at 4:31 PM | gurufocus.comGilead Sciences, Inc. (NASDAQ:GILD) Position Raised by Principal Financial Group Inc.Principal Financial Group Inc. grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,451,249 shares of the biopharmaceutical company's stock after acquirDecember 21 at 4:56 AM | marketbeat.comGilead Sciences to Present at Upcoming Investor ConferenceDecember 20 at 4:05 PM | businesswire.comGilead Sciences, Inc. (NASDAQ:GILD) Receives $96.43 Average Target Price from AnalystsDecember 20 at 2:43 AM | americanbankingnews.comCash is Down, Valuations Are Up, but Stay InvestedDecember 19 at 7:04 PM | investorplace.comAssembly Biosciences announces $30.1M investment, funding from GileadDecember 19 at 2:11 PM | markets.businessinsider.comGilead raises Assembly Bio stake to ~30%December 19 at 2:11 PM | msn.comGilead Sciences (NASDAQ:GILD) & Immatics (NASDAQ:IMTX) Head-To-Head AnalysisDecember 19 at 4:15 AM | americanbankingnews.comBiotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX GainsDecember 18, 2024 | msn.comGilead: A Large-Cap Pharma With Limited Patent Cliff ExposureDecember 18, 2024 | seekingalpha.comGilead Sciences’ Buy Rating Affirmed on HIV Market Potential and Strategic Leadership ChangesDecember 17, 2024 | markets.businessinsider.comAndrew D. Dickinson Sells 8,500 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) StockGilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CFO Andrew D. Dickinson sold 8,500 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $91.96, for a total transaction of $781,660.00. Following the sale, the chief financial officer now directly owns 132,373 shares of the company's stock, valued at approximately $12,173,021.08. This trade represents a 6.03 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.December 17, 2024 | marketbeat.comGilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule TherapiesDecember 17, 2024 | finance.yahoo.comFDA Grants Breakthrough Therapy Status To Gilead's Trodelvy For Treatment Of Small Cell Lung CancerDecember 17, 2024 | markets.businessinsider.comGilead Inks Strategic Collaboration With Terray Therapeutics To Develop Small Molecule TherapiesDecember 17, 2024 | markets.businessinsider.comGilead gets FDA breakthrough therapy status for TrodelvyDecember 17, 2024 | msn.comGilead, Terray to collaborate on small molecule drugsDecember 17, 2024 | msn.comU.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung CancerDecember 17, 2024 | businesswire.comB. Riley Wealth Advisors Inc. Sells 15,668 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)B. Riley Wealth Advisors Inc. decreased its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 43.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,006 shares of the biopharmaceutical companyDecember 17, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Sees Large Increase in Short InterestGilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) was the recipient of a large increase in short interest in November. As of November 30th, there was short interest totalling 23,410,000 shares, an increase of 29.6% from the November 15th total of 18,060,000 shares. Based on an average daily volume of 6,840,000 shares, the days-to-cover ratio is currently 3.4 days. Currently, 1.9% of the company's stock are sold short.December 15, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Franklin Resources Inc.Franklin Resources Inc. raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 22.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,241,354 shares of thDecember 15, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Synovus Financial CorpSynovus Financial Corp lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 99.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 37,265 shares of the biopharmaceutical company's stock after buyingDecember 15, 2024 | marketbeat.comWilmington Savings Fund Society FSB Has $1.56 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)Wilmington Savings Fund Society FSB increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 278.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,660 shareDecember 15, 2024 | marketbeat.comWorld Investment Advisors LLC Has $2.18 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)World Investment Advisors LLC grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 33.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 25,999 shares of the biopharmaceutDecember 15, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twenty-seven ratings firms that are covering the company, MarketBeat.com reports. Twelve equities research analysts have rated the stock with a hold recommendation, twelve haveDecember 15, 2024 | marketbeat.com50,000 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Exome Asset Management LLCExome Asset Management LLC acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 50,000 shares of the biopharmaceutical company's stocDecember 14, 2024 | marketbeat.comGilead gets positive EU regulatory opinion for seladelparDecember 14, 2024 | msn.comGilead Sciences (GILD) Gets a Hold from Truist FinancialDecember 14, 2024 | markets.businessinsider.comGilead Sciences (GILD) Stock Moves -0.57%: What You Should KnowDecember 14, 2024 | msn.comZacks Research Weighs in on Gilead Sciences FY2025 EarningsDecember 14, 2024 | americanbankingnews.comGilead Sciences Says Seladelpar Gets Positive CHMP Opinion For Primary Biliary CholangitisDecember 13, 2024 | markets.businessinsider.comGilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary CholangitisDecember 13, 2024 | finance.yahoo.comRetirement Systems of Alabama Cuts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Retirement Systems of Alabama cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 761,854 shares of the biopharmaceutical company'December 13, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by American TrustAmerican Trust cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 18.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,059 shares of the biopharmaceutical company's stock after selling 6,16December 13, 2024 | marketbeat.comTri Ri Asset Management Corp Buys Shares of 40,314 Gilead Sciences, Inc. (NASDAQ:GILD)Tri Ri Asset Management Corp bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 40,314 shares of the biopharmaceutical coDecember 13, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Tidal Investments LLCTidal Investments LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 9.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 111,464 shares of the bioDecember 13, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Stock Position Lifted by Sanctuary Advisors LLCSanctuary Advisors LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 28.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 183,289 shares of the biopharmaceuticalDecember 13, 2024 | marketbeat.comGilead Sciences Inc (GILD) Receives Positive CHMP Opinion for Seladelpar in Treating Primary ...December 13, 2024 | gurufocus.comLeerink Partnrs Lifts Earnings Estimates for Gilead SciencesGilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Stock analysts at Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for shares of Gilead Sciences in a research note issued on Wednesday, December 11th. Leerink Partnrs analyst D. Graybosch now expects that the biopharmaceutDecember 13, 2024 | marketbeat.comGilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary CholangitisDecember 13, 2024 | businesswire.comGilead Sciences, Inc. (NASDAQ:GILD) Position Trimmed by TCW Group Inc.TCW Group Inc. trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 83.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 29,934 shares of the biopharmaceutical company's stock afDecember 13, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Teachers Retirement System of The State of KentuckyTeachers Retirement System of The State of Kentucky lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 93,388 shares of tDecember 13, 2024 | marketbeat.comXTX Topco Ltd Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)XTX Topco Ltd purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 6,924 shares of the biopharmaceutical company's stock, valued at approximatelyDecember 13, 2024 | marketbeat.comLooking For Yields: IDACORP, Gilead Sciences and Fifth Third Bancorp Are Consistent MoneymakersDecember 12, 2024 | finance.yahoo.comGilead Sciences’ Anito-Cel Shows Promising Efficacy and Safety in Phase 2 Trial, Earning Buy RatingDecember 12, 2024 | markets.businessinsider.comGilead Sciences Appoints New Chief Medical Officer to Strengthen Leadership in Virology and OncologyDecember 12, 2024 | gurufocus.comGilead appoints Sanofi official Dietmar Berger as next chief medical officerDecember 12, 2024 | reuters.comGilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical OfficerDecember 12, 2024 | businesswire.comBlankinship & Foster LLC Takes $1.01 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)Blankinship & Foster LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 12,000 shares of the biopharmaceutical company's stock, valued at approximatelyDecember 12, 2024 | marketbeat.comArvest Bank Trust Division Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)Arvest Bank Trust Division purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 115,226 shares of the biophaDecember 12, 2024 | marketbeat.com Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED. Click here to see the details because I believe a lot of people will get rich. GILD Media Mentions By Week GILD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GILD News Sentiment▼0.710.61▲Average Medical News Sentiment GILD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GILD Articles This Week▼2121▲GILD Articles Average Week Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AMGN News Today VRTX News Today REGN News Today ALNY News Today BIIB News Today UTHR News Today INCY News Today NBIX News Today BMRN News Today EXAS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GILD) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gilead Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gilead Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GILD Stock Alerts